Achieving MFS and Improved Quality of Life in nmCRPC With Darolutamide
Karim Fizazi, MD, PhD,head of the Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Sud, gives highlights on the updated findings from the phase III ARAMIS trial using darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer, recently presented during the 2019 ASCO Annual Meeting. <br />
Karim Fizazi, MD, PhD,head of the Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Sud, gives highlights on the updated findings from the phase III ARAMIS trial using darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), recently presented during the 2019 ASCO Annual Meeting.
As a result of the phase III ARAMIS trial,darolutamide was recently granted a priority review designation by the FDAfor treatment of nmCRPC.
TheARAMIS studywas designed to address the aspects of nmCRPC that directly impact the patientie, disease symptoms, prostate-specific antigen (PSA) and anxiety, quality of life, and survival. With 1590 patients randomized 2:1 to receive either 600 mg of darolutamide twice daily (n = 955) or placebo (n = 554), the aim was to achieve a primary endpoint of improved metastasis-free survival (MFS) and 2 secondary endpoints, overall survival (OS) and time to pain progression.
With darolutamide, quality of life in patients was maintained and symptoms were prevented. Specifically, subjects in the darolutamide arm showed more delay in pain progression (HR, 0.65; 95% CI, 0.53-0.79;P
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
